Webinar: Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment (2020)

September 2, 2020

Course Director:  Benjamin R. Lee, MD

Treatment of renal cell carcinoma has changed with expanding indications for Robotic Partial nephrectomy and inclusion of new FDA approved treatments for advanced RCC. This course will focus on didactic case discussions using video tape analysis of surgical treatment, setup and successful completion of Robotic Partial nephrectomy, complication management and how to optimize outcomes. Urologists are now faced with treatment of advanced RCC with a host of options, from tyrosine kinase inhibitors to checkpoint inhibitors. There will be discussion focus on how to monitor, and algorithms for when to switch treatment.

Acknowledgements:

This educational activity is supported by independent educational grants from:

  •  Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. State how to manage bleeding complications of robotic partial nephrectomy.
  2. Describe the algorithm of Immunotherapy treatment of advanced Renal Cell Carcinoma.
  3. Explain how to minimize positive margin rates of robotic partial nephrectomy.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
08/21/2020
Course expires: 
09/02/2023
Event starts: 
09/02/2020 - 5:00pm EDT
Event ends: 
09/02/2020 - 6:30pm EDT
Part of: 
Summer School Webinar Series (2020)
Add to calendar: 
Rating: 
0

Scientific Agenda

All times are Eastern

5:00 pm               Welcome, Housekeeping Notes, Knowledge Assessment

5:10 pm               Faculty Introduction/Learning Objectives

Benjamin R Lee MD, University of Arizona College of Medicine

5:13 pm               Advanced RCC management: TKIs, Immunotherapy, checkpoint inhibitors.  Which to use & when to switch.  

Oliver Sartor MD, Tulane Cancer Center and Tulane Medical School                                       

5:40 pm               Complications Panel:  Tips & Tricks for getting out of trouble, Video analysis

Benjamin R Lee MD                               

6:05 pm               Case Discussion: Challenging Management dilemmas

Chandru Sundaram MD, University of Indiana       

6:30 pm               Adjourn and Credit Claim Instructions

 

Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment (2020) will be held virtually on Wednesday, September 2 at 5:00 PM EST.

***Instructions***

Click here to join the webinar. 

Prior to joining, you will be taken to a GoToWebinar registration page; follow the instructions to be let into the webinar. 

Education Council Disclosures

PDF icon Education Council & COI Reviewer Disclosure_090220.pdf

AUA Office of Education Staff has nothing to disclose.

 

Course Director(s)

Benjamin Lee, MD

has no relevant financial relationships to disclose at this time.
Faculty(s)

A. Oliver Sartor, MD

has a financial relationship (Independent contractor) with Endocyte;.
has a financial relationship (Independent contractor) with Myovant;.
has a financial relationship (Independent contractor) with Constellation;.
has a financial relationship (Independent contractor) with Bavarian Nordic;.
has a financial relationship (Independent contractor) with Advancel Accelerator Applications (AAA);.
has a financial relationship (Independent contractor) with Myriad;.
has a financial relationship (Independent contractor) with EMD Serono;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Other) with Invitae;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Myriad;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Other) with Invitae;.
has a financial relationship (Independent contractor) with Noxopharm;.
has a financial relationship (Independent contractor) with Endocyte;.
has a financial relationship (Independent contractor) with Bristol Myers Squibb;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Noxopharm;.
has a financial relationship (Independent contractor) with Bristol Myers Squibb;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Jannsen;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Progenics;.
has a financial relationship (Independent contractor) with Advancel Accelerator Applications (AAA);.
has a financial relationship (Independent contractor) with EMD Serono;.
has a financial relationship (Independent contractor) with Jannsen;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Progenics;.
has a financial relationship (Independent contractor) with Myovant;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Constellation;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Bavarian Nordic;.

Chandru Sundaram, MD

has a financial relationship (Independent contractor) with Journal of Endourology;.
has a financial relationship (Independent contractor) with Endourological Society;.
has a financial relationship (Independent contractor) with Journal of Endourology;.
has a financial relationship (Independent contractor) with Endourological Society;.

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA Participant Information and Policies

DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.

REPRODUCTION PERMISSION: 

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.

Click "Take Course" and then click on the provided link to register then join the webinar.